TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03545438

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo
Study: NCT01129375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study: NCT02668445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal containing low or high carbohydrate content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal containing low or high carbohydrate content
Study: NCT01976104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (lower baseline platelet count)
Description: 60 mg avatrombopag (3 x 20 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (lower baseline platelet count)
Description: 60 mg placebo (3 x 20 mg matching placebo tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (higher baseline platelet count)
Description: 40 mg avatrombopag (2 x 20 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (higher baseline platelet count)
Description: 40 mg placebo (2 x 20 mg matching placebo tablets)
Study: NCT04624282

Intervention type: DIAGNOSTIC_TEST
Intervention: different diseases
Description: Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.

Intervention type: DIAGNOSTIC_TEST
Intervention: different diseases
Description: Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.

Intervention type: DIAGNOSTIC_TEST
Intervention: different diseases
Description: Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
Study: NCT03063931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium: Magnésium UPSA Action Continue®
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Lactose
Description: This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
Study: NCT00665366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Participant's ongoing dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Participant's ongoing dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: Participant's ongoing dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproate
Description: Participant's ongoing dose
Study: NCT03176576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN)
Description: Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaire
Description: Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline Questionnaire
Description: Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Questionnaire
Description: After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up Questionnaire
Description: After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator Satisfaction Survey
Description: Evaluation of Patient Navigator intervention process.
Study: NCT04851704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
Study: NCT01147432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: Single dose IV infusion up to 300mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge
Description: Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion (saline) to be administered during two of the three treatment periods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin challenge
Description: Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA positive control
Description: 2g EMLA cream to be applied ONCE during study period 1
Study: NCT02696837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal LMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Muscle Relaxant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Muscle Relaxant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study: NCT01129375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: matching tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral
Study: NCT02223637

Intervention type: BIOLOGICAL
Intervention: Meningococcal quadrivalent CRM-197 conjugate vaccine
Description: This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
Study: NCT04174443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-voltage pulsed radiofrequency
Description: 2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency
Description: 2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-temperature continuous radiofrequency
Description: Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
Study: NCT01976325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ottawa Malaria Decision Aid
Description: The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
Study: NCT01789476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845
Description: CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered using same dosing algorithm as the active arm
Study: NCT03362411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single 100 mg dose on Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single 100 mg dose on Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single 100 mg dose on Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Single 100 mg dose on Day 1 and Day 15
Study: NCT04275830

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Surveys
Description: Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Heart rate variability waitlist and Digital storytelling Control intervention
Description: Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
Study: NCT00656669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib alone
Description: sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib plus paclitaxel
Description: sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin and cyclophosphamide
Description: doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
Study: NCT02822729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: DE-117 ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Timolol ophthalmic solution
Study: NCT03931902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation with Endotracheal tube
Description: After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intubation with laryngeal mask airway
Description: After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
Study: NCT02058264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000
Study: NCT00679042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islets of Langerhans transplantation
Description: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant
Study: NCT01302821

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon C 11 alpha-methyltryptophan
Description: The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
Study: NCT03814954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
Study: NCT02457325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with 2%Articaine first, then Surgery with 4% Articaine
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
Study: NCT03638479

Intervention type: OTHER
Intervention: Data Capture
Description: This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.

Intervention type: OTHER
Intervention: Data Capture
Description: This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.

Intervention type: OTHER
Intervention: Data Capture
Description: This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
Study: NCT03545438

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo
Study: NCT02965027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Study: NCT02085694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2
Study: NCT02965027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01329562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet matching Treximet for oral administration.
Study: NCT00761735

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peginterferon alfa-2b
Description: In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Study: NCT02229188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
Study: NCT03115320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin
Description: Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Home ovulation test
Description: The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
Study: NCT03352544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training for 12 weeks (aerobic and resistance training trice a week)
Study: NCT02229188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evolution
Description: Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Words
Description: Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
Study: NCT02457325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery with 4%Articaine first, then Surgery with 2% Articaine
Description: First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
Study: NCT01374308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NASVAC
Description: NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha 2b
Description: Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
Study: NCT03385239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 678354
Description: ISIS 678354 solution for SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl).
Study: NCT04361461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
Study: NCT03194919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
Study: NCT02689765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Description: Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules is identically packaged.
Study: NCT04132973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion for Skin Conditions
Description: Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).